| Total: $422.05M | ||||
| Company (Symbol)# | Type Of Financing | Number Of Shares, Units Or Warrants (M) | Amount Raised (M) | Investors; Placement Agents; Details (Date)@ |
| Advanced Cell Technology Inc. (OTC BB:ACTC) | Private placement of senior secured convertible debenture | N/A | $10 | Advanced Cell raised $10M in a private placement (9/4) |
| Antigenics Inc. (AGEN) | Private placement of common stock | 1.6S | $5 | Antigenics is selling $5M in stock to Fletcher Asset Management, issuing 1.6M shares at $3.08 each (9/6) |
| Avicena Group Inc. (OTC BB: AVGO) | Private placement of preferred stock | 3.1S | $3.1 | Avicena raised $3.1M in an initial closing of its private offering of 3.1M shares of Series C convertible preferred stock, which are convertible at $3.35 per share into 928,358 shares, and warrants (9/26) |
| Barrier Therapeutics Inc. (BTRX) | Registered direct offering | 5.5S | $31.9 | Barrier raised about $31.9M in an offering of 5.5M shares at $5.75 each to a group of institutional investors; J.P. Morgan Securities acted as the exclusive placement agent and Pacific Growth Equities LLC served as financial advisor (9/24) |
| BioForce Nanosciences Holdings Inc. (OTC BB:BFNH) | Private placement of 8% convertible preferred stock and warrants | N/A | $0.5 | BioForce raised $500,000 in the private sale (9/4) |
| Biofrontera AG(Germany;FSE:B8F) | Private placement | 0.22S | €3.1 ($4.4) | Biofrontera raised $4.4M by issuing 220,582 new shares, priced at E15 each (9/26**) |
| Corcept Therapeutics Inc. (CORT) | Private placement of common stock | 4.8S | $10.1 | Corcept raised $10.1M in a private placement of 4.8M shares at $2.10 each (9/25) |
| Devgen NV (Belgium; BR:DEVG) | Investment | 1S | €18 ($25) |
Monsanto Co. is subscribing to about 1M Devgen shares at $23.88 each (9/17) |
| EntreMed Inc. (ENMD) | Secured loan agreement | N/A | $20 | EntreMed entered the agreement with a syndicate led by GE Healthcare Financial Services and including Merrill Lynch Capital and Oxford Finance Corp. (9/17) |
| Genelabs Technologies Inc. (GNLB) | Private placement of common stock and warrants | 12.9S and W for 2.6S | $23.7 | Genelabs raised $23.7M through the sale; Deutsche Bank Securities Inc. acted as exclusive placement agent (9/26) |
| Medicure Inc. (Canada; AMEX:MCU) | Financing agreement | N/A | $25 | Medicure raised $25M through an agreement with Elliott Associates LP (9/24) |
| MediGene AG (Germany; FSE:MDG) | Private placement of common stock | 3.1S | €15.6 ($21.5) | MediGene raised $21.5M through the placement of 3.1M shares at E5.05 per share (9/10) |
| Medivation Inc. (MDVN) | Credit facility | N/A | Medivation could bring in up to $100M through the facility with Azimuth Opportunity Ltd. over an 18 month period (9/10) | |
|
MicroIslet Inc. (OTC BB:MIIS) |
Bridge loan | N/A | $1 | An existing investor agreed to lend the company $1M to bridge its working capital needs until additional funding can be secured (9/21) |
| Millennium Biotechnologies Group Inc. (OTC BB:MBTG) | Private placement of securities | N/A | $2.28 | Millennium raised $2.28M in a private placement (9/10) |
| Nanobac Pharmaceuticals Inc. (OTC BB:NNBP) | Interim debt financing | N/A | ND | Nanobac said its board approved an interim debt financing (9/27) |
| Prana Biotechnology Ltd. (Australia; PRAN; ASX:PBT) | Private placement of common stock | 24.6S | A$7 ($5.9) | Prana raised $5.9M through a private placement of about 24.6M shares priced at A28.5 cents apiece; Brimberg & Co. assisted Prana with the transaction |
| ProMetic Life Sciences Inc. (Canada; TSX:PLI) | Private placement of stock | 11.6S and 5.5S | C$6.6 ($6.3) | ProMetic raised $6.3M, offering 13.3M shares to Paradigm Capital Inc., and 5.6M shares to U.S. institutional investors (9/4) |
| Senesco Technologies Inc. (AMEX:SNT) | Private placement of secured convertible debentures | N/A | $5 | Senesco raised $5M through a placement of secured convertible debentures with an 8% coupon maturing Dec. 31, 2010 (9/4) |
| ThromboGenics NV (Belgium; BR:THR) | Exercise of warrants | 1.1W | €5.1 ($7.2) | ThromboGenics raised $7.2M through the exercise of 1.1M warrants (9/20) |
| Notes: | ||||
| This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Funds from loan facilities are included only when the company takes a draw, if announced. # Unless otherwise indicated, shares are traded on the Nasdaq exchange @ Refers to the date of the press release.** Denotes the date the item ran in BioWorld International. Currency conversions are based on exchange rates at the time of the deal.N/A = Not applicable; ND = Not disclosed. AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSX = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.